Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2003 Feb 24;13(4):697-700.

Orally efficacious NR2B-selective NMDA receptor antagonists.

Author information

1
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA.

Abstract

A novel series of benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 31 is orally active in a carrageenan-induced rat hyperalgesia model of pain and shows no motor coordination side effects.

PMID:
12639561
DOI:
10.1016/s0960-894x(02)01061-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center